Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Fareed

Showing results (341-350 of 384) with videos related to

Pageof 39
Sort By:
International Angiology : a Journal of the International Union of Angiology|November 1, 2008
Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfateM Clark, D Hoppensteadt, J Walenga, et al.
Psychotherapy and Psychosomatics|January 1, 1989
Hostile personality characteristics and prostaglandins in essential hypertensionS Aritzi, J Demakis, G Demakis, et al.
Seminars in Thrombosis and Hemostasis|June 5, 1999
Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopeniaK F Izban, H W Lietz, D A Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|February 24, 2001
Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgeryS I Hakki, J Fareed, D A Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 4, 2007
Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsisThyyar M Ravindranath, Masakatsu Goto, Omer Iqbal, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 9, 2001
Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88)M Demir, O Iqbal, D A Hoppensteadt, et al.
American Journal of Clinical Pathology|October 1, 1990
Global and molecular hemostatic markers in acute myeloid leukemiaV B Reddy, A Kowal-Vern, D A Hoppensteadt, et al.
International Angiology : a Journal of the International Union of Angiology|November 12, 2013
Association between serum levels of pro-metalloproteinase 1, tissue inhibitor of metalloproteinases 1 and 2 and prevalent cardiovascular disease in a population-based studyA G Panayiotou, E Kamilari, M Griffin, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 13, 2000
Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgeryS I Hakki, J Fareed, D A Hoppensteadt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopeniaM A Rosenthal, D Rischin, G McArthur, et al.
Pageof 39

Showing results (341-350 of 384) with videos related to

Sort By:
Pageof 39
International Angiology : a Journal of the International Union of Angiology|November 1, 2008
Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfateM Clark, D Hoppensteadt, J Walenga, et al.
Psychotherapy and Psychosomatics|January 1, 1989
Hostile personality characteristics and prostaglandins in essential hypertensionS Aritzi, J Demakis, G Demakis, et al.
Seminars in Thrombosis and Hemostasis|June 5, 1999
Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopeniaK F Izban, H W Lietz, D A Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|February 24, 2001
Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgeryS I Hakki, J Fareed, D A Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 4, 2007
Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsisThyyar M Ravindranath, Masakatsu Goto, Omer Iqbal, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 9, 2001
Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88)M Demir, O Iqbal, D A Hoppensteadt, et al.
American Journal of Clinical Pathology|October 1, 1990
Global and molecular hemostatic markers in acute myeloid leukemiaV B Reddy, A Kowal-Vern, D A Hoppensteadt, et al.
International Angiology : a Journal of the International Union of Angiology|November 12, 2013
Association between serum levels of pro-metalloproteinase 1, tissue inhibitor of metalloproteinases 1 and 2 and prevalent cardiovascular disease in a population-based studyA G Panayiotou, E Kamilari, M Griffin, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 13, 2000
Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgeryS I Hakki, J Fareed, D A Hoppensteadt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopeniaM A Rosenthal, D Rischin, G McArthur, et al.
Pageof 39